Elena Moreno-Olmedo

RadOnc-MRL-consultant at @harleystclinic @HCAhospitalsUK. AdaptiveRT. MRIguided.HDR-BT. SABR. Prostate, Gyn, H&N, Oligomets.

[Elena Moreno-Olmedo @elenmol2]

🧵Glad to share our 10y results at #ASTRO23.
🔎looking for the biological benefit of ultrahypofractionation, safety and confort of the patient and cost-effectiveness of the process, this prospective study was initiated in 2010.

[David Woolf @ClinOncologist]

Presenting our data showing the benefits of SABR in OPD alongside systemic therapy. #ESTRO26
@GenesisCare @drjamesgood @crispinhiley @OwczarczykKasia @elenmol2 @PaulGearing1

[Gerry Hanna @gerryhanna]

Super paper by @elenmol2 et al from @ucl + @TheChristieNHS on #MRLinac guided central lung #SABR

📢Check out the amazing cine movies of adaption to target on the journal website (screenshot below)
➡️No grade ≥ 3 toxicities
➡️Median FU of 28 months, 66.7% of patients alive
➡️Median PFS = 5.8 months, OS = 20 months

🔗 https://t.co/b9s3kWi0dJ

[Pierre Blanchard, MD @PBlanchardMD]

STOPCAP at #ESMO26

Benefit of #radiotherapy in de novo M1 #prostatecancer on OS & PFS.

Restricted to <5 bone or low volume mets on conventional imaging.

No interaction with other patient/tumor characteristics.

[Daniel E Spratt @DrSpratticus]

As expected people resist letting go of dogma. Lets review the common examples people grasp at:

1. Nodal field size: cited as why GETUG01 was negative (S1/S2), then cited why RTOG 9413 was negative (L5/S1), then POP-RT positive (L4/L5), but definitive trial of RTOG 0924 (L4/L5) negative

[Daniel E Spratt @DrSpratticus]

#astro25

@NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT.

Negative trial
-OS no difference
-PCSM no difference
-DM no difference
-BCR was not SS different with only 4% difference at 10 years.
-toxicity increased

3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924.

Goodbye WPRT

[Dr. Andrew Loblaw @DrAndrewLoblaw]

Critically important. We have 2 RCTs addressing this question: @GiulioFrancoli1 #ARTO (MDT + abi > abi) and T Niazi #PCS IX (MDT + Enza > Enza)

Also have #EXTEND and #RADIOSA showing MDT + ADT > ADT or MDT in mHSCP.

In my mind leading question is doublet ARPI + MDT in mHSPC

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Continuous Androgen Deprivation Therapy with or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: The Multicenter Phase 2 Randomized EXTEND Trial

https://t.co/oADg5v1pEf

The phase 2 EXTEND trial showed that in patients with oligometastatic #ProstateCancer adding metastasis-directed therapy (MDT) to androgen deprivation therapy (ADT)💊 significantly improved progression-free survival compared with ADT alone (36 vs 17 months in combined analysis), with consistent benefits in radiologic and castration resistance–free survival; translational analyses revealed that MDT + ADT enhanced systemic immune activation, particularly T-cell receptor dynamics, suggesting both a durable clinical benefit and potential synergy with future immunotherapy strategies.

@AlexSherryMD
@BSiddiquiMD
@cara_haymaker
@ASeoMDPhD
@kieko_hara
@StephenChunMD
@ChapinMD
@matthewdeek
@woodlandscancer
@aaparicioMD
@DrLCohen
@AReubenPhD
@sumit_subudhi
@ChadTangMD

@silkegillessen @AOmlin
@nataliagandur @bavilima @yekeduz_emre

[Angel Montero Luis @Monthy_A]

High-risk prostate cancer patients had a significantly lower incidence of distant metastasis with a radiotherapy-based treatment strategy than with a prostatectomy-based treatment #radonc #pcsm
https://t.co/MAaCYKkfXU

[Elena Moreno-Olmedo @elenmol2]

MR- vs CT-guided: nearly half GU toxicity!!💥💥💥

[European Urology @EUplatinum]

📢 New in European Urology @AmarUKishan et al:

🎯 MRI-guided SBRT for prostate cancer significantly reduces late GU and GI toxicity vs CT-guided SBRT at 2 years!

🔬 In the MIRAGE RCT, MRI guidance with tighter margins (2 mm) halved GU toxicity (27% vs 51%) and markedly reduced GI toxicity (1.4% vs 9.5%).

💡 Also linked to better bowel & sexual function scores. Proof-of-principle for aggressive margin reduction using advanced imaging.

📄 Read more: https://t.co/ShEUaJCD4p
#ProstateCancer #Radiotherapy #MRI #SBRT #UroRadOnc #EurUrol

[European Urology @EUplatinum]

📢 New in European Urology @AmarUKishan et al:

🎯 MRI-guided SBRT for prostate cancer significantly reduces late GU and GI toxicity vs CT-guided SBRT at 2 years!

🔬 In the MIRAGE RCT, MRI guidance with tighter margins (2 mm) halved GU toxicity (27% vs 51%) and markedly reduced GI toxicity (1.4% vs 9.5%).

💡 Also linked to better bowel & sexual function scores. Proof-of-principle for aggressive margin reduction using advanced imaging.

📄 Read more: https://t.co/ShEUaJCD4p
#ProstateCancer #Radiotherapy #MRI #SBRT #UroRadOnc #EurUrol

[Angel Montero Luis @Monthy_A]

📢The experience from @RadioterapiaHM is just out!!

🎯Clinician- And Patient-Reported Outcomes Of Stereotactic Ablative Radiotherapy For High-Risk Prostate Cancer
#radonc #pcsm #SABR
https://t.co/e0vflOqcPC

[European Association of Urology (EAU) @Uroweb]

🧾 New Cheat Sheet on Prostate Cancer Treatment by Stage

🔹 Low-risk: Active surveillance; avoid ADT
🔹 Intermediate-risk: Surgery or RT; ADT case-based
🔹 High-risk: Surgery/RT + long-term ADT

#EAUguidelines #ProstateCancer

Download Cheat Sheet here:
https://t.co/IvTGHuFWt6

[Shankar Siva @_ShankarSiva]

📢This might just be THE DEFINITIVE meta-analysis of PSMA PET for #prostatecancer recurrence.
🚨Meta-analysis of 43 studies (n=8,119)
⬆️Sensitivity from 48% at PSA 0.2–0.5 ng/ml to >90% at PSA >2. Congrats @declangmurphy @drMPerera + team @Uroweb!
➡️link https://t.co/VYvAn6kli1

[GenesisCareUK @GenesisCare]

Proud to see EMERALD Trial findings presented at #ESTRO2025 by Dr. Somnath Mukherjee! Watch this short video from @drjamesgood to discover how MR-guided SABR is transforming pancreatic cancer treatment 🎥

Click to download ESTRO presentation 👉🏽 https://t.co/nU6gPp3eE5

[Elena Moreno-Olmedo @elenmol2]

That’s a wrap #ESTRO25! ⁦@ESTRO_RT⁩ Proud to see the hard work&commitement of the ⁦⁦⁦@GenesisCare⁩ to providing experience-based evidence in the pursuit of clinical improvement! Here our contribution to #SMART using MRIdian on #upperGI https://t.co/5p10Kk0lxy

[Piet Ost @piet_ost]

SBRT + 💊 in oligomets:
🧍‍♂️2294 pts | 🫁, breast, prostate, colorectal
⚠️Grade 3+ AEs: 1.5%
✅ SBRT Safe with systemic tx!
#SBRT #OligoCare #ESTRO25 @EORTC @ESTRO_RT @CiroFranzese1

[Elena Moreno-Olmedo @elenmol2]

☢️For those interested in more technical details, don’t miss our dosimetric poster (E25-3471)!!

[Elena Moreno-Olmedo @elenmol2]

💎 EMERALD trial in #ESTRO25
Congratulations Dr. Mukherjee for excellent presentation! Honored to have worked w/you.
🎯 3-arm safety trial investigating #SMART in localised #PancreaticCancer (50 Gy/5, 39 Gy/3, 25 Gy/1)
👏🏽Big shout-out to all authors
@GenesisCare @UniofOxford

[Elena Moreno-Olmedo @elenmol2]

Massive thanks for the support and collaboration to @GenesisCare UK , @UniofOxford and @NHSEngland (OUH)

[Pierre Blanchard, MD @PBlanchardMD]

🚨10y results of HYPO RT PC at #ESTRO25

Hypofractionated #prostatecancer RT (42,7/7) vs conv fractionated RT
1. Non inferior for FFS (even better?)
2. Similar bPFS, DMFS, ADT use, OS
3. Similar GU/GI tox (except transient flare at 1y for UHF)